Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Did You Know Previous | All Articles This Week | Next
This article originally posted and appeared in  MedicationSGLT2Issue 731

Empagliflozin (an SGLT2 inhibitor) Approved by European Commission

The European Commission has approved empagliflozin 10 mg and 25 mg once-daily tablets for use in adults when glycemic control is not achieved from diet and exercise. The European Commission endorsed empagliflozin for approval in March after the U.S. FDA delayed the approval and requested more data. A new drug application has been accepted by the FDA for a combination of empagliflozin and linagliptin, though, and will be reviewed. This approval is based on more than 10 international trials looking at more than 13,000 adults with type 2 diabetes. The phase 3 studies produced significantly reduced HbA1c, body weight and blood pressure when used as monotherapy and in combination with preexisting treatments. Lilly News Release, Mau 2014 

Advertisement
Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 29 May, 2014 and appeared in  MedicationSGLT2Issue 731

Past five issues: Diabetes Clinical Mastery Series Issue 208 | Issue 748 | GLP-1 Special Editions September 2014 | Diabetes Clinical Mastery Series Issue 207 | Issue 747 |

2014 Most Popular Articles:

Abbott Announces Approval of Its New Unique Continuous Glucose Monitor
Posted September 05, 2014
Low Carb Beats Low Fat
Posted September 05, 2014
FDA Approves Bupropion/Naltrexone (Contrave) for Obesity by Orexigen Therapeutics
Posted September 12, 2014
Lilly's Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus
Posted September 05, 2014
An Exclusive Interview with Al Mann, Founder and CEO, Mannkind Corp.
Posted September 15, 2014
Sleeve Gastrectomy Now a Common Choice for Bariatric Surgery
Posted September 12, 2014
Type 2 Diabetes Diagnosis Needs to Be Changed: Prediabetes=Diabetes
Posted September 12, 2014
Predicting Which Diabetics Will Develop Major Complications
Posted September 05, 2014
Empagliflozin (Jardiance) SGLT-2 Inhibitor Now Available in Pharmacies
Posted August 29, 2014
High-salt Diet and High HBA1c May Increase Cardiovascular Disease
Posted September 19, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Now that once-weekly dulaglutide has been approved, will you be prescribing it?
CME/CE of the Week
Vickie Driver, DPM, MS, FACFAS

Category: Wound Care
Credits: 1.0



Search Articles On Diabetes In Control